Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00490568
Registration number
NCT00490568
Ethics application status
Date submitted
21/06/2007
Date registered
22/06/2007
Date last updated
13/11/2017
Titles & IDs
Public title
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
Query!
Scientific title
An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.
Query!
Secondary ID [1]
0
0
AVA102675
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Rosiglitazone XR
Experimental: Rosiglitazone XR - Investigational drug
Treatment: Drugs: Rosiglitazone XR
Experimental drug
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Any Adverse Events (AEs) and Severity of AEs
Query!
Assessment method [1]
0
0
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of the AE'S was categorized as mild, moderate and severe. Number of participants reporting AEs during the on treatment phase of the study.
Query!
Timepoint [1]
0
0
Up to 76 Weeks
Query!
Secondary outcome [1]
0
0
Number Participants With Serious Adverse Events (SAEs) and Deaths
Query!
Assessment method [1]
0
0
A SAE is defined as any untoward medical occurrence that, at any dose results in death, is a life-threatening condition, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or a congenital anomaly or birth defect. Number of participants with SAEs and deaths were reported for treatment duration of the study.
Query!
Timepoint [1]
0
0
Up to 76 Weeks
Query!
Secondary outcome [2]
0
0
Number of Participants With Adverse Event of Oedema
Query!
Assessment method [2]
0
0
Oedema was considered as adverse event of special interest (AESI). The process for AESI selection was based on RSG's pharmacologic class and relevant AEs potentially associated with RSG. The number of participants and their percentage for the adverse event of the various types of oedema were reported.
Query!
Timepoint [2]
0
0
Up to 76 Weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in Vital Sign Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Query!
Assessment method [3]
0
0
Vital signs SBP and DBP were measured at each visit. All measurements were made on the participant non-dominant arm supported at heart level, using the same cuff size and same equipment. Blood pressure was measured once, after the participant sat quietly for at least 5 minutes. DBP was measured at the disappearance of Korotkoff sounds (Phase V). If the participant was a smoker or used tobacco products, a period of 30 minutes without tobacco was allowed before taking these measurements. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the blood pressure value recorded at specified visit minus the Baseline value.
Query!
Timepoint [3]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [4]
0
0
Change From Baseline in Vital Sign Heart Rate (HR)
Query!
Assessment method [4]
0
0
Vital sign HR was measured at each visit. HR was measured once, after the participant sat quietly for at least 5 minutes. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the HR at specified visit minus the Baseline value.
Query!
Timepoint [4]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [5]
0
0
Change From Baseline in Vital Sign Body Weight (BW)
Query!
Assessment method [5]
0
0
BW was measured at all visits, without shoes and wearing light clothing. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the body weight at specified visit minus the Baseline value.
Query!
Timepoint [5]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [6]
0
0
Change From Baseline in Non-fasting Measures of Lipid Metabolism Namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides
Query!
Assessment method [6]
0
0
The clinical chemistry data included non-fasting measures of lipid metabolism (TC,HDL,LDL,triglycerides). Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication. Change from Baseline was measured as the lipids (TC,HDL,LDL,triglycerides) value recorded at specified visit minus the Baseline value.
Query!
Timepoint [6]
0
0
Up to 82 Weeks (including follow up)
Query!
Secondary outcome [7]
0
0
Number of Participants With SBP and DBP Values of Potential Clinical Concern (PCC)
Query!
Assessment method [7]
0
0
The frequency of participant vital sign sitting blood pressure was obtained to check if the values lie outside of a pre-determined reference range (RR) for SBP 90-140 mmHg, DBP 50-90 mmHg or have a change from Baseline of PCC for SBP increase from Baseline (IFB) \>=40, decrease from Baseline (DFB) \>= 30 for and for DBP (IFB) \>= 30 ,DFB \>= 20. The number of participants with values of PCC at any time on treatment (ATOT) and follow up were reported.
Query!
Timepoint [7]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [8]
0
0
Number of Participants With HR Values of PCC ATOT
Query!
Assessment method [8]
0
0
HR was measured once, after the participant sat quietly for at least 5 minutes. The frequency of participant vital sign heart rate was obtained to check if the values lie outside of a pre-determined reference range (RR) 50-100 bpm or have a change from Baseline of PCC IFB \>=30 and DFB \>=30. The number of participants with values of PCC including follow up were reported.
Query!
Timepoint [8]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [9]
0
0
Number of Participants With BW Values of PCC ATOT
Query!
Assessment method [9]
0
0
The frequency of participant vital sign weight was obtained to check if the values have CFB of PCC IFB \>=7 percent. With the exception of Week 4, when participants were first titrated to the 8mg RSG XR dose, at every time point in the study where weight was measured the percentage of participants experienced an increase in BW of PCC was approximately 2 times greater than the percentage of participants experiencing an decrease in BW of PCC DFB \>=7 percent. The number of participants with values of PCC including follow up were reported.
Query!
Timepoint [9]
0
0
Up to 70 Weeks (including follow up)
Query!
Secondary outcome [10]
0
0
Number of Participants With Hematology Parameters of PCC ATOT
Query!
Assessment method [10]
0
0
The hematology data included eosinophils, haematocrit, haemoglobin, lymphocytes, mean corpuscular haemoglobin (MCH), mean corpuscular volume (MCV), monocytes, platelet count, red cell distribution width (RDW), red blood cell (RBC) count, segmented neutrophils (SN), total neutrophils (TN), white blood cell (WBC) count. The number of participants with values of PCC (defined as high and low) ATOT were reported.
Query!
Timepoint [10]
0
0
Up to Week 82 (including follow up)
Query!
Secondary outcome [11]
0
0
Number of Participants With Clinical Chemistry Parameters (Including Lipids) of PCC ATOT
Query!
Assessment method [11]
0
0
The clinical chemistry data included alanine amino transferase (ALT), albumin, aldolase, asparatate amino transferase (AST), BUN/creatinine ratio, carbon dioxide(CO2) content, chloride, cholesterol, creatinine kinase (CK), creatinine, direct bilirubin (DB), gamma glutamyl transferase (GGT), glucose, glycosylated Hemoglobin (HbA1C), HDL, LDL, lactate dehydrogenase (LD), magnesium, potassium, sodium, total bilirubin (TB), triglycerides, troponin I, urea. The number of participants with values of PCC (defined as high and low) ATOT were reported.
Query!
Timepoint [11]
0
0
Up to Week 82 (including follow up)
Query!
Secondary outcome [12]
0
0
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score as a Function of Apolipoprotein E (APOE) e4 Status.
Query!
Assessment method [12]
0
0
The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores ranged from 0 to 70 with higher scores indicating greater dysfunction. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point.
Query!
Timepoint [12]
0
0
Baseline (Week 0) and Week 24, 52
Query!
Secondary outcome [13]
0
0
Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score as a Function of APOE e4 Status.
Query!
Assessment method [13]
0
0
The CDR-SB is a validated clinical assessment of global function in par. with Alzheimer's disease (AD). Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or box scores, were added together to give the CDR-Sum of Boxes which ranged from 0 to 18 (severe impairment). Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point.
Query!
Timepoint [13]
0
0
Baseline (Week 0) and Week 24, 52
Query!
Secondary outcome [14]
0
0
Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE e4 Status.
Query!
Assessment method [14]
0
0
The MMSE consisted of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores ranged from 0 to 30, with lower scores indicating greater cognitive impairment. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point.
Query!
Timepoint [14]
0
0
Baseline (Week 0) and Week 24, 52
Query!
Secondary outcome [15]
0
0
Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOE e4 Status.
Query!
Assessment method [15]
0
0
DAD, assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assesses a participant's ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD total score/total number of applicable items) \* 100. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point.
Query!
Timepoint [15]
0
0
Baseline (Week 0) and Week 24, 52
Query!
Secondary outcome [16]
0
0
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE e4 Status.
Query!
Assessment method [16]
0
0
12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, motor disturbance, appetite, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions=participant has problems with a particular sub-domain of behavior, the caregiver asked all the questions about that domain, rating the frequency (1=occasionally to 4=very frequently) on a 4-point scale, their severity (1=Mild to 3=Severe) on a 3-point scale, and the distress on a 5-point scale. Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances. Baseline for the open-label study was the latest assessment from Week 48 of parent studies to the first dose of open-label medication (Week 0). Change from Baseline was calculated as the Baseline value minus the value at the specified time point.
Query!
Timepoint [16]
0
0
Baseline (Week 0) and Week 24, 52
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Successful completion of AVA102670 or AVA102672 without safety or tolerability issues. Regular caregiver.
Query!
Minimum age
51
Years
Query!
Query!
Maximum age
91
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Congestive Heart Failure (NYHA 1-4), clinically significant peripheral edema, other neurological conditions that might disqualify participation. SAE, clinically significant laboratory abnormality or significant cardiovascular event during prior study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/08/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1461
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Hornsby
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Randwick
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Auchenflower
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Chermside
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Kippa Ring
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Woodville
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Cheltenham
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - Heidelberg Heights
Query!
Recruitment hospital [9]
0
0
GSK Investigational Site - Kew
Query!
Recruitment hospital [10]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2077 - Hornsby
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [4]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [5]
0
0
4021 - Kippa Ring
Query!
Recruitment postcode(s) [6]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [7]
0
0
3192 - Cheltenham
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg Heights
Query!
Recruitment postcode(s) [9]
0
0
3101 - Kew
Query!
Recruitment postcode(s) [10]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Rhode Island
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Utah
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Vermont
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Wisconsin
Query!
Country [21]
0
0
Argentina
Query!
State/province [21]
0
0
Buenos Aires
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Córdova
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Mendoza
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Hall in Tirol
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Vienna
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Kortrijk
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Leuven
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Woluwe-Saint-Lambert
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Sofia
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Varna
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
New Brunswick
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Nova Scotia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Prince Edward Island
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Saskatchewan
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Québec
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Región Metro De Santiago
Query!
Country [40]
0
0
Chile
Query!
State/province [40]
0
0
Valparaíso
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Olomouc
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Ostrava
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Praha 10
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Praha 2
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 5
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha 7
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Praha 8
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Trutnov
Query!
Country [49]
0
0
Finland
Query!
State/province [49]
0
0
Helsinki
Query!
Country [50]
0
0
Finland
Query!
State/province [50]
0
0
Kuopio
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Bourg en Bresse
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Caen
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Dijon
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Ivry
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
La Seyne sur Mer
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Lille
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Limoges
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Luynes
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Lyon
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Marseille
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Metz
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Nantes
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Nice
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Paris
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Pau
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Rodez
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Saint Ouen la Rouerie
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Saint-Etienne
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Sautron
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Tinteniac
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Toulon
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Toulouse
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Tours
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Vichy
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Baden-Wuerttemberg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Bayern
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Brandenburg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Hessen
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Mecklenburg-Vorpommern
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Niedersachsen
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Nordrhein-Westfalen
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Sachsen
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Thueringen
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Berlin
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Hamburg
Query!
Country [86]
0
0
Greece
Query!
State/province [86]
0
0
Athens
Query!
Country [87]
0
0
Greece
Query!
State/province [87]
0
0
Melissia
Query!
Country [88]
0
0
Greece
Query!
State/province [88]
0
0
Thessaloniki
Query!
Country [89]
0
0
Hong Kong
Query!
State/province [89]
0
0
Hong Kong
Query!
Country [90]
0
0
Hong Kong
Query!
State/province [90]
0
0
Shatin
Query!
Country [91]
0
0
Hungary
Query!
State/province [91]
0
0
Gyor
Query!
Country [92]
0
0
Hungary
Query!
State/province [92]
0
0
Szeged
Query!
Country [93]
0
0
India
Query!
State/province [93]
0
0
Hyderabad
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Nagpur
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
New Delhi
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
Pune
Query!
Country [97]
0
0
India
Query!
State/province [97]
0
0
Varanasi
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Abruzzo
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Campania
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Lazio
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Lombardia
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Marche
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Toscana
Query!
Country [104]
0
0
Korea, Republic of
Query!
State/province [104]
0
0
Seongnam-si,
Query!
Country [105]
0
0
Korea, Republic of
Query!
State/province [105]
0
0
Seoul
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Nuevo León
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Mexico
Query!
Country [108]
0
0
Netherlands
Query!
State/province [108]
0
0
Alkmaar
Query!
Country [109]
0
0
Netherlands
Query!
State/province [109]
0
0
Blaricum
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Den Bosch
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Den Haag
Query!
Country [112]
0
0
Netherlands
Query!
State/province [112]
0
0
Hengelo
Query!
Country [113]
0
0
Netherlands
Query!
State/province [113]
0
0
Hilversum
Query!
Country [114]
0
0
Philippines
Query!
State/province [114]
0
0
Pasig City
Query!
Country [115]
0
0
Poland
Query!
State/province [115]
0
0
Bydgoszcz
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Katowice
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Mosina
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Poznan
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Sopot
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Warsaw
Query!
Country [121]
0
0
Portugal
Query!
State/province [121]
0
0
Coimbra
Query!
Country [122]
0
0
Portugal
Query!
State/province [122]
0
0
Lisboa
Query!
Country [123]
0
0
Slovakia
Query!
State/province [123]
0
0
Bratislava
Query!
Country [124]
0
0
Slovakia
Query!
State/province [124]
0
0
Kosice
Query!
Country [125]
0
0
Slovenia
Query!
State/province [125]
0
0
Ljubljana
Query!
Country [126]
0
0
Slovenia
Query!
State/province [126]
0
0
Šempeter
Query!
Country [127]
0
0
South Africa
Query!
State/province [127]
0
0
Loeventstein
Query!
Country [128]
0
0
South Africa
Query!
State/province [128]
0
0
Oakdale
Query!
Country [129]
0
0
South Africa
Query!
State/province [129]
0
0
Richards Bay
Query!
Country [130]
0
0
South Africa
Query!
State/province [130]
0
0
Rosebank
Query!
Country [131]
0
0
South Africa
Query!
State/province [131]
0
0
Somerset West
Query!
Country [132]
0
0
South Africa
Query!
State/province [132]
0
0
Waverley, Bloemfontein
Query!
Country [133]
0
0
South Africa
Query!
State/province [133]
0
0
Willows, X14, Pretoria
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Barcelona
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Burgos
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Castellón
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Elche (Alicante)
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Gerona
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Madrid
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Murcia
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Palma de Mallorca
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Tarrasa, Barcelona
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
Valencia
Query!
Country [144]
0
0
Sweden
Query!
State/province [144]
0
0
Jönköping
Query!
Country [145]
0
0
Sweden
Query!
State/province [145]
0
0
Kalix
Query!
Country [146]
0
0
Sweden
Query!
State/province [146]
0
0
Mölndal
Query!
Country [147]
0
0
Sweden
Query!
State/province [147]
0
0
Sundsvall
Query!
Country [148]
0
0
Sweden
Query!
State/province [148]
0
0
Umeå
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Lancashire
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Bradford
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Liverpool
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
West of Scotland Science Park, Glasgow
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672. All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR as adjunctive therapy to their existing dose of acetylcholinesterase inhibitor. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed either AVA102670 or AVA102672. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00490568
Query!
Trial related presentations / publications
Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011 Aug;8(5):592-606. doi: 10.2174/156720511796391935.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00490568
Download to PDF